课题基金 / 基金详情

Genetic Transformation of Chlamydia

Genetic Transformation of Chlamydia
衣原体的遗传转化
批准号:
6227846
负责人:
HARLAN D CALDWELL
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

HARLAN D CALDWELL的其他基金

相似基金

相关文献

中文摘要
翻译
沙眼衣原体是专性细胞内细菌,是人类性传播疾病(STD)的最常见原因。女性生殖器感染的常见后遗症是输卵管炎,可导致盆腔炎(PID)和不孕。据估计,治疗衣原体性传播疾病每年要花费50亿美元。尽管在了解衣原体性传播疾病的发病机制方面取得了很大进展,但在感染的病理生理学和免疫学方面仍有一些关键的未解问题,这些问题阻碍了急需的预防性治疗方法的发展。实现这一目标的一个主要障碍是无法使用分子遗传学方法来研究这一重要的人类病原体。只有当对病原体进行基因操作成为可能时,在控制衣原体性传播疾病方面可能会取得重大进展。基因组学的最新进展大大增加了开发许多致病微生物研究新策略的可行性。对于衣原体来说确实如此。例如,完整的沙眼衣原体基因组序列的可用性表明,该生物体具有基因重组和修复所需的相当完整的基因补体。这表明,建立衣原体遗传转化系统是可行的。这个项目的目的是开始开发衣原体遗传系统的过程。一旦遗传学的基本工具开发出来,该项目将解决旨在确定最佳DNA导入和转化方法的其他挑战。这些将包括使用电穿孔和粒子轰击技术靶向生物体的感染性细胞外和非感染性细胞内生命形式。一旦稳定的遗传转化条件被开发出来,将进行实验来突变或敲除从基因组序列中确定的潜在重要毒力决定因素的目标基因,并将新的基因引入衣原体基因组,这可能使生物体能够在细胞外生长。这些研究的结果将显著促进对衣原体致病机制和疾病过程的理解,并可能为开发新的减毒活生物体提供见解,这些生物体可以在衣原体感染的临床前模型中作为候选疫苗进行测试。到目前为止,我们已经使用最近描述的斑块克隆程序分离自发性利福平抗性突变沙眼衣原体。稳定的遗传抗性标记的开发将使我们能够测试沙眼衣原体在电穿孔或粒子轰击方法引入后整合DNA的能力。-空斑测定、克隆、抗生素耐药性、重组、电穿孔、粒子轰击和DNA诱变
英文摘要
Chlamydial trachomatis are obligate intracellular bacteria and are the most common cause of sexually transmitted diseases (STD) of humans. A common sequelae of genital infection of women is salpingitis that can lead to pelvic inflammatory disease (PID) and infertility. Treatment of chlamydial STDs is estimated to cost 5 billion dollars annually. Although much progress has been made in understanding the pathogenesis of chlamydial STD there remains key unanswered questions in the pathophysiology and immunology of infection that have hampered advances in the development of much needed preventive therapies. A major obstacle toward this end has been the inability to use molecular genetic approaches to study this important human pathogen. It is likely that significant progress in the control of chlamydial STD will only come when genetic manipulation of the pathogen is possible. Recent advances in genomics have greatly increased the feasibility of developing new strategies for the study of many pathogenic microorganisms. This is indeed true for Chlamydia. For example, the availability of the complete C. trachomatis genomic sequence shows that the organism possess a reasonably complete complement of genes necessary for genetic recombination and repair. This strongly suggests that it should be feasible to develop a genetic transformation system for chlamydiae. The purpose of this project is to begin the process of developing a genetic system for Chlamydia. Once the basic tools of genetics are developed the project will address other challenges aimed at defining methods for optimum DNA introduction and transformation. These will include the targeting of both the infectious extracellular and non-infectious intracellular life forms of the organism using electroporation and particle bombardment technologies. Once conditions for stable genetic transformation have been developed experiments will be done to mutate or knock out targeted genes identified from the genome sequence as potentially important virulence determinants, and introduce new genes into the chlamydial genome that might allow the organism to be grown outside cells. The results of these studies should significantly advance the understanding of chlamydial pathogenic mechanism(s) and disease processes, as well as possibly produce insights for the development of novel live-attenuated organisms that can be tested as vaccine candidates in pre-clinical models of chlamydial infection. To date we have used the recently described plaque cloning procedure to isolate spontaneous rifampicin resistant mutants of C. trachomatis. The development of stable genetic resistance markers will enable us to test the ability of C. trachomatis to incorporate DNA following introduction by electroporation or particle bombardment means. - Plaque assay, cloning, antibiotic resistance, recombination, electroporation, particle bombardment, and DNA mutagenesis
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chlamydial Immunity and Vaccine Development
Immunity to Chlamydial Infection
Pathogenomics of Chlamydial Infection
Immunity To Chlamydial Infection
海外基金